Literature DB >> 20843257

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Matthew J Armstrong, Diarmaid D Houlihan, Ian A Rowe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20843257     DOI： 10.1056/NEJMc1006581

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Schisandra chinensis Baill, a Chinese medicinal herb, alleviates high-fat-diet-inducing non-alcoholic steatohepatitis in rats.

Authors:  Zheng Yao; Xiao-Chen Liu; Ying-Er Gu
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-11-02

Review 2.  Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk.

Authors:  Lucia Pacifico; Valerio Nobili; Caterina Anania; Paola Verdecchia; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2011-07-14       Impact factor: 5.742

3.  Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice.

Authors:  Chunming Jia; Yi Huan; Shuainan Liu; Shaocong Hou; Sujuan Sun; Caina Li; Quan Liu; Qian Jiang; Yue Wang; Zhufang Shen
Journal:  Int J Mol Sci       Date:  2015-05-29       Impact factor: 5.923

4.  Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles.

Authors:  Xinlu Yuan; Jie Wang; Xiaoyan Tang; Yixue Li; Pu Xia; Xin Gao
Journal:  J Transl Med       Date:  2015-01-27       Impact factor: 5.531

5.  Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice.

Authors:  Jun Peng; Yi Huan; Qian Jiang; Su-Juan Sun; Chun-Ming Jia; Zhu-Fang Shen
Journal:  PPAR Res       Date:  2014-03-31       Impact factor: 4.964

Review 6.  Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression.

Authors:  Krishna Chaitanya Thandra; Adam Barsouk; Kalyan Saginala; John Sukumar Aluru; Prashanth Rawla; Alexander Barsouk
Journal:  Clin Exp Hepatol       Date:  2020-12-30

7.  The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.

Authors:  Mohamed Abdel-Maboud; Amr Menshawy; Esraa Menshawy; Amany Emara; Mohamed Alshandidy; Muhammad Eid
Journal:  Therap Adv Gastroenterol       Date:  2020-12-07       Impact factor: 4.409

8.  Anti-lipoapoptotic effect of Artemisia capillaris extract on free fatty acids-induced HepG2 cells.

Authors:  Eungyeong Jang; Min-Hee Shin; Ki-Suk Kim; Yoomi Kim; Yun-Cheol Na; Hong-Jung Woo; Youngchul Kim; Jang-Hoon Lee; Hyeung-Jin Jang
Journal:  BMC Complement Altern Med       Date:  2014-07-19       Impact factor: 3.659

Review 9.  Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches.

Authors:  Óscar Soto-Angona; Gerard Anmella; María José Valdés-Florido; Nieves De Uribe-Viloria; Andre F Carvalho; Brenda W J H Penninx; Michael Berk
Journal:  BMC Med       Date:  2020-10-01       Impact factor: 8.775
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.